Citius Pharmaceuticals, Inc. (CTXR) vs Vyome Holdings, Inc. (HIND)
A side-by-side comparison of Citius Pharmaceuticals, Inc. and Vyome Holdings, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTXR
Citius Pharmaceuticals, Inc.
$0.51HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
HIND
Vyome Holdings, Inc.
$1.97HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
Total return — CTXR vs HIND
growth of $100 · dividends reinvested · last 10yCTXR -99.8% (-45.7%/yr)HIND -100.0% (-84.2%/yr)CTXR compounded faster over this window
Log scale — wide-divergence pair
CTXR HIND
CTXR vs HIND: by the numbers
- •CTXR is the larger company ($14M vs $14M market cap).
- •Both run net losses; CTXR's is the smaller (-651.27% vs -8716.77% net margin).
Metrics side by side
Valuation
| Metric | CTXR | HIND |
|---|---|---|
| P/S ratio | 1.98 | 106.58 |
| P/B ratio | 0.21 | 2.29 |
| FCF yield | N/A | 3.79% |
Profitability
| Metric | CTXR | HIND |
|---|---|---|
| Gross margin | 0.00% | 64.68% |
| Operating margin | 0.00% | -859.22% |
| Net margin | -651.27% | -8716.77% |
| ROE | -69.47% | -186.95% |
| ROIC | -67.62% | -57.53% |
Growth (annualized)
| Metric | CTXR | HIND |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -60.54% |
| Total return CAGR (5Y) | -60.04% | -92.93% |
Frequently asked
- How have CTXR and HIND total returns compared?
- Over the past 5 years, CTXR delivered -60.04% and HIND delivered -92.93% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.